Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of PF-06252616 in Boys with Duchenne Muscular Dystrophy
2016-001615-21Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of domagrozumab in Duchenne muscular dystrophy (DMD), sponsored by Pfizer. Primary endpoint: Long-term safety of PF-06252616. Started Oct 2016; status: terminated.
02
Drugs
domagrozumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2016-001615-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001615-21.